Medicenna Therapeutics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Selling, General & Admin	5.57	5.96	7.87	7	7.76	6.53
Research & Development	16.25	14.44	10.8	9.3	14.72	10.87
Operating Expenses	21.82	20.41	18.67	16.3	22.47	17.4
Operating Income	-21.82	-20.41	-18.67	-16.3	-22.47	-17.4
Interest & Investment Income	1	1.35	1.2	0.91	0.07	0.31
Currency Exchange Gain (Loss)	0.39	0.9	-0.07	1.65	-0.17	-0.21
Other Non Operating Income (Expenses)	6.61	6.35	-7.92	3.7	-	-
EBT Excluding Unusual Items	-13.82	-11.81	-25.47	-10.05	-22.58	-17.29
Pretax Income	-13.82	-11.81	-25.47	-10.05	-22.58	-17.29
Net Income	-13.82	-11.81	-25.47	-10.05	-22.58	-17.29
Net Income to Common	-13.82	-11.81	-25.47	-10.05	-22.58	-17.29
Shares Outstanding (Basic)	81	77	70	65	54	50
Shares Outstanding (Diluted)	81	77	70	65	54	50
Shares Change (YoY)	11.18%	10.10%	7.57%	19.25%	9.31%	55.68%
EPS (Basic)	-0.17	-0.15	-0.37	-0.16	-0.42	-0.35
EPS (Diluted)	-0.17	-0.15	-0.37	-0.16	-0.42	-0.35
Free Cash Flow	-17.03	-16.53	-16.26	-12.66	-23.58	-15.31
Free Cash Flow Per Share	-0.21	-0.22	-0.23	-0.20	-0.43	-0.31
EBITDA	-21.8	-20.39	-18.67	-16.3	-22.44	-17.36
D&A For EBITDA	0.02	0.02	0	0	0.04	0.04
EBIT	-21.82	-20.41	-18.67	-16.3	-22.47	-17.4

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.